Skip to content
PubMed This is a summary of 9 peer-reviewed journal articles Updated
Hepatology · Acute Intermittent Porphyria

Long-Term Health Risks and Surveillance in AIP

At a Glance

Patients with Acute Intermittent Porphyria (AIP) face increased long-term risks for primary liver cancer, chronic kidney disease, and chronic high blood pressure. Routine surveillance, including annual imaging and blood tests starting around age 50, is vital for early detection and management.

While managing acute attacks is the immediate priority in Acute Intermittent Porphyria (AIP), it is equally important to look toward the future. Because AIP affects metabolic pathways throughout the body, it can lead to chronic health issues that require lifelong vigilance. By staying ahead of these risks through regular surveillance, you can take control of your long-term health.

The Risk of Liver Cancer

Patients with AIP, particularly those who have experienced symptoms or high levels of toxic precursors (ALA and PBG), have a significantly higher risk of developing hepatocellular carcinoma (HCC), a type of primary liver cancer [1][2].

What makes AIP-related liver cancer unique is that it can occur even if the liver appears healthy and has no scarring (cirrhosis) [3]. The risk increases with age and is higher in those who have had recurrent attacks [4][5]. While reading about cancer risk can be anxiety-inducing, remember that routine screening is highly effective at catching it early when it is most treatable.

  • Surveillance Schedule: Specialists generally recommend an annual abdominal ultrasound and an alpha-fetoprotein (AFP) blood test [3].
  • When to Start: For most patients who have experienced symptoms, screening typically begins at age 50 [3]. In some cases, such as those with other risk factors like viral hepatitis or heavy alcohol use, your doctor may suggest starting earlier [4].

Protecting Your Kidneys

Chronic Kidney Disease (CKD) is one of the most common long-term complications of AIP [6]. This happens for two reasons: the high levels of toxic precursors can be hard on the delicate filters of the kidneys, and many AIP patients develop chronic high blood pressure, which further damages the kidneys over time [3][6].

To protect your kidney health, your care team should monitor:

  • eGFR (Estimated Glomerular Filtration Rate): A blood test that measures how well your kidneys are filtering waste [3].
  • Serum Creatinine: A waste product that builds up if the kidneys are not working properly [3].
  • Protein in the Urine: An early sign of kidney stress [3].

Managing Chronic Hypertension

High blood pressure (hypertension) is common during an acute attack because of the stress on the nervous system [7]. However, for many patients, this high blood pressure becomes a permanent condition [8][9].

Left untreated, chronic hypertension accelerates kidney damage and increases the risk of heart disease. It is vital to use porphyria-safe blood pressure medications [8]. While many standard medications are safe, some (like certain calcium channel blockers) may be triggers, so always verify your prescriptions against a safety database [3].

Summary of Long-Term Monitoring

Condition Monitoring Test Recommended Frequency
Liver Cancer (HCC) Abdominal Ultrasound + AFP Blood Test Every 6 to 12 months (starting at age 50)
Kidney Disease (CKD) eGFR and Serum Creatinine At least once per year
Hypertension Blood Pressure Check Every doctor’s visit (or home monitoring)

The Psychological Toll of “Watchful Waiting”

Living with a chronic condition that requires constant monitoring can be emotionally draining. It is normal to feel “scan-xiety”—the stress that builds up before annual checkups. Remember that these screenings are not just about finding problems; they are about giving you the peace of mind that you are doing everything possible to stay healthy. Early detection is the most effective tool for successful treatment [3].

Common questions in this guide

What are the long-term health risks of Acute Intermittent Porphyria?
The primary long-term risks include primary liver cancer (hepatocellular carcinoma), chronic kidney disease, and chronic high blood pressure. These issues develop due to the long-term effects of toxic precursors and metabolic stress on the body.
When should I start screening for liver cancer with AIP?
For most patients who have experienced AIP symptoms, specialists recommend starting annual liver ultrasounds and AFP blood tests at age 50. If you have additional risk factors like heavy alcohol use, your doctor may suggest starting earlier.
Why does AIP cause chronic kidney disease?
AIP can cause kidney disease because high levels of toxic precursors damage the delicate filters in your kidneys. The chronic high blood pressure that many patients develop also puts additional stress on kidney function over time.
Can I take standard blood pressure medications if I have AIP?
While many standard blood pressure medications are safe, some can trigger porphyria attacks. It is critical to always verify any new prescription against a porphyria safety database and consult your specialist to ensure it is safe for you.
How often should my kidney function be checked?
Your doctor should monitor your kidney function at least once a year. This usually involves checking your eGFR, serum creatinine levels, and testing for protein in your urine to catch any early signs of kidney stress.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Since I have a diagnosis of AIP, what is our specific schedule for liver cancer screening (imaging and blood work)?
  2. 2.Can you review my blood pressure readings from the last few months to see if they are consistently high even between attacks?
  3. 3.Which blood pressure medications are considered 'safe' for someone with my genetic mutation?
  4. 4.What is my current eGFR (kidney function score), and how has it changed over the last few years?
  5. 5.At what age should we start annual liver ultrasounds for me, based on my symptom history?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (9)
  1. 1

    Liver transplantation and primary liver cancer in porphyria.

    Lissing M, Wang B, Wahlin S

    Liver international : official journal of the International Association for the Study of the Liver 2025; (45(3)):e15894 doi:10.1111/liv.15894.

    PMID: 38456621
  2. 2

    Causal effect of porphyria biomarkers on alcohol-related hepatocellular carcinoma through Mendelian Randomization.

    Yang X, Wang S, Sun C, Xia Y

    PloS one 2024; (19(3)):e0299536 doi:10.1371/journal.pone.0299536.

    PMID: 38507434
  3. 3

    Acute Hepatic Porphyrias: Review and Recent Progress.

    Wang B, Rudnick S, Cengia B, Bonkovsky HL

    Hepatology communications 2019; (3(2)):193-206 doi:10.1002/hep4.1297.

    PMID: 30766957
  4. 4

    Hepatocellular Carcinoma in Acute Hepatic Porphyria: A Meta-Analysis of Observational Studies.

    Singal AK, Reddy RK, Gudiwada MC, et al.

    Digestive diseases and sciences 2024; (69(11)):4268-4274 doi:10.1007/s10620-024-08661-w.

    PMID: 39438413
  5. 5

    Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review.

    Ramai D, Deliwala SS, Chandan S, et al.

    Cancers 2022; (14(12)) doi:10.3390/cancers14122947.

    PMID: 35740611
  6. 6

    Long-term complications in acute porphyria.

    Pischik E, Lissing M, Pallet N, Kauppinen R

    Liver international : official journal of the International Association for the Study of the Liver 2024; (44(9)):2197-2207 doi:10.1111/liv.15966.

    PMID: 38819621
  7. 7

    Discovery of Porphyria in a Postoperative Surgical Patient.

    Toteja N, Khera D, Panda S, et al.

    Indian journal of pediatrics 2021; (88(4)):412 doi:10.1007/s12098-020-03631-2.

    PMID: 33420636
  8. 8

    [Research Progress in Pathogenesis of Hypertension in Acute Intermittent Porphyria].

    Li QY, Ren Y, Wang JH, Yang J

    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 2023; (45(1)):129-133 doi:10.3881/j.issn.1000-503X.14571.

    PMID: 36861166
  9. 9

    Risk for incident comorbidities, nonhepatic cancer and mortality in acute hepatic porphyria: A matched cohort study in 1244 individuals.

    Lissing M, Vassiliou D, Floderus Y, et al.

    Journal of inherited metabolic disease 2023; (46(2)):286-299 doi:10.1002/jimd.12583.

    PMID: 36546345

This page provides information on long-term health risks and surveillance for AIP for educational purposes only. Always consult your healthcare provider or a porphyria specialist for personalized medical advice and to establish your screening schedule.

Get notified when new evidence is published on HMBS-related hepatic porphyria.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.